C&R Research(CEO Moon-Tae Yoon) announced today that it will hold its second webinar on October 29th. The webinar, titled 'LNR (Lab Normal Range) Mastery: From Raw Data to Reliable Insights,' will provide an in-depth, integrated guide for the proper collection and application of Lab data in clinical trials.LNR is essential for safety evaluation and ensuring data reliability in clinical trials, but it carries a high risk of errors, particularly in long-term, multi-center studies. This webinar will predict potential errors that can occur during the data collection process and propose practical quality control strategies applicable to real-world scenarios.The webinar will consist of two main sessions:In the first session, Heon-Chul Ha, Team Leader 1 of Data Management at C&R Research's Information Division, will present 'Collect it Right: Error Prevention in Lab Normal Range Collection.' This session will introduce solutions aimed at minimizing errors during the LNR collection phase.In the second session, Jin-Seok Kim, Team Leader 3, will discuss 'Beyond Collection: Quality Management & Regulatory Alignment.' He will analyze the risks associated with applying LNR to EDC (Electronic Data Capture), propose standardized management strategies, and present effective management methods through real-world case studies.Sook-Jeong Cho, Vice President of C&R Research's Information Division, stated, "This webinar will offer practical solutions to systematically resolve the difficulties in LNR management. We believe it will provide clinical professionals with valuable insights and enhance their practical competitiveness through our differentiated strategies and real-world application cases."The webinar is free and registration is available through the official C&R Research website. Pre-registration is open until the 24th of this month. Access links will be sent individually via email to pre-registered attendees.  Read the text | PHarmnews

   Strengthen your strategic partner status  C&R Research announced on the 26th that it successfully concluded the event with differentiated expertise and on-site communication at Asia's largest clinical conference "2025 Conference on International Clinical Trials (KIC)."KIC, which marks its 11th anniversary this year, held various programs such as conferences and exhibitions under the theme of "Innovation of Clinical Trials through Technology, Diversity, and Cooperation," and more than 1,500 people, including bio and clinical experts, participated in the event from 20 countries around the world.Through the operation of the booth, C&R Research focused the attention of clinical industry officials such as pharmaceutical companies, biotech companies, and hospitals. At this meeting, we exchanged the core capabilities of C&R Research for integrated whole-cycle clinical services and discussed in-depth partnering with participants to explore the possibility of future cooperation.In addition, we conducted a joint survey with family members (GCL, Trial Informatics, TI Images, C&RSMO, and ABC Bioscience) on the overall organically connected pre-cycle services. It received great response as a place to identify the needs of the industry and listen to the voices of participants.In particular, the presentation session presented by C&R Research at this KIC presented a key strategy to look at the future of new drug development by conducting under the themes of innovative statistical design techniques of early clinical trials (Vice President Cho Sook-jung), Korea's global clinical trial hub background and know-how of C&R (Kim Yun-ho, managing director) and DSUR strategic use of new drug development (Hwang So-yeon, part leader)."This KIC is an important place to broaden the horizon of cooperation by sharing C&R Research's overall clinical trial strategy and rich global experience," said Yoon Moon-tae, CEO of C&R Research. "We will use this as a stepping stone to solidify our position as a strategic partner with domestic and foreign pharmaceutical ？ bio companies and grow as a strong partner in new drug development." Read the text | Hankyung

  The only CRO company to participate...Emphasis on the core competitiveness of the bio industryC&R Research, a clinical trial trustee (CRO), announced on the 17th that it was the only CRO company to participate in the 'Korea Investment Week (KIW) 2025', the largest investment event in Korea, on the 16th and made a presentation under the theme of 'Strategy to Maximize Clinical Trial Efficiency'.This year's event was held at the Conrad Seoul Hotel under the theme of "COSPI 5000, Age of Daejeon Transformation," highlighting key industries that will lead to long-term stock market growth. In particular, the bio-industry drew attention in terms of high value-added industries and technological innovation potential, and CRO-related sessions were organized.In a clinical trial environment where regulations are recently strengthened, CRO is evolving beyond simple consignment agencies to become a strategic partner in new drug development. CRO's expertise in integrating the entire clinical trial process and leading collaboration among stakeholders is evaluated as a key factor for the success of new drug development."The government's large-scale R&D investment is boosting candidate development and overseas expansion," said Kim Jin-hak, head of C&R Research's U.S. subsidiary. "As a result, demand for clinical trials is expected to continue to increase, maximizing the efficiency of new drug development is an important competitiveness of the bio industry."C&R Research has advanced clinical trial innovation based on its global network and professional capabilities, he said. "We are ready to take off with the industry to strengthen international competitiveness in the future." Read the text | Pharmnews       

    CRO C&R Research, which specializes in clinical trials, announced on the 9th that it will be a three-session speaker at the "2025 KIC" held at Lotte Hotel in Jung-gu, Seoul for three days from the 22nd to the 24th.Through this lecture, we will share innovation strategies across clinical trials, from initial clinical statistics to safety management and global clinical performance know-how, and share innovation achievements in global clinical trials.Cho Sook-jung, vice president of the Intelligence Headquarters, will give a lecture on 'Statistical Innovation in Early Stage Clinical Trials'. In this lecture, we will introduce innovative statistical design techniques to establish an optimal dose range that is safe and effective in the early clinical stage. This is expected to serve as an opportunity to raise awareness of the importance of early clinical trials in the new drug development process.Kim Yoon-ho, managing director of the business division, will present the theme of "Cost-Effective Global Trials: What We Learned After Execution." We will introduce C&R Research's global clinical strategy and know-how through real-world examples along with the background of Korea becoming a global clinical trial hub.Hwang So-yeon, the head of the information division, will give a lecture on Development Safety Update Reports (DSUR): Role, Strategic Applications, and Key Considers. It introduces the role of DSUR in the development of new drugs and key considerations when writing them, and deals with how pharmaceutical companies can strategically use DSUR based on their actual experiences.In addition, C&R Research will strengthen on-site communication by introducing its capabilities as a CRO specializing in global clinical trials through a promotional booth.  Read the text | Medipana

  CNR Research (CEO Yoon Moon-tae) announced on the 2nd that it will participate as an educator in the "Digital Treatment Device (DTx) Clinical Practice Course" organized by the National Clinical Trials Support Foundation (KoNECT) on the 19th. In this course, team leader Lee Eun-joo of the medical device team at CNR Research will be an instructor to conduct training on how to write clinical trial protocols.This training was newly established to cultivate clinical experts in digital treatment devices, which have recently been in increasing demand, and was selected as an education partner in recognition of CNR Research's clinical trial expertise.In the lecture, Team Leader Eunjoo Lee will share the basic principles of clinical trial design and practical experience required when writing actual protocols. In addition, we plan to deal with the strategic approach to follow-up clinical trials and deliver practical know-how that can be applied directly in the field.Team leader Lee Eun-joo said, "We will share CNR Research's accumulated experience in the clinical field of digital treatment devices through education and contribute to the growth of practitioners into professional manpower."On the other hand, this training is for biotech R&D workers and clinical trial managers related to digital treatment devices, and can be applied through the KoNECT website by the 7th.  Read the text | Pharmnews

  C&R Research announced on the 29th that the first official webinar, "The Journey of Anti-cancer Treatment Innovation, held by precision strikes toward targets and antibody drug conjugates (ADC), has been successfully completed.ADC, a key platform for precision chemotherapy, has grown by more than 20% annually in the global market, highlighting its importance. With the recent announcement of guidelines for the U.S. Food and Drug Administration (FDA) and the domestic Food and Drug Administration, the industry's interest has grown, and it has been successful amid high interest.The webinar was highly well received by participants as MD Jung Yong-joo, a medical advisor at C&R Research's information headquarters, followed by MD Lim Eun-soo's in-depth "Scientific Understanding and Future of ADC" and "Development Strategy through Permission Cases."In particular, ADC's structure, mechanism of action, effectiveness and safety, as well as practical insights into new drug development through representative success case analysis, were evaluated to enhance participants' professional understanding.Ahn Byung-jin, president of C&R Research's operations division, said, "This webinar was the first step in leading innovation to quench the thirst for ADC new drug development and was a signal of C&R webinar. We will continue to hold beneficial webinars reflecting industrial trends in the future to serve as leaders in clinical development."Meanwhile, the second C&R webinar will be held on October 29, and the presentation will be made by Ha Heon-cheol, head of the C&R Research DM1 team, and Kim Jin-seok, head of the DM3 team, under the theme of Lab Normal Range Mastery.   Read the text | Hankyung